1 injection of potent juice every 39-52 weeks for RA patients who are resistant to or intolerant of anti-TNF or other biologic agents.
At 12, 39 and 52 weeks:
- the MPC 2M/kg group significantly outperformed placebo at every time point for ACR-N Area Under the Curve (AUC) (p=0.05 at 12 weeks, p=0.004 at 39 weeks, and p=0.008 at 52 weeks), indicating a robust, durable and consistent clinical effect of this MPC dose.
Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell, page-3
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.033(2.01%) |
Mkt cap ! $2.105B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.67 | $1.61 | $3.031M | 1.851M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 16318 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 24295 | 23 |
View Market Depth
| Last trade - 11.30am 04/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |